Our mission is to enable access to life changing gene therapies and help bring them from idea into r
Location: United States, Ohio, Columbus
Employees: 51-200
Total raised: $250M
Founded date: 2020
Investors 5
| Date | Name | Website |
| 10.11.2023 | Aisling Ca... | aislingcap... |
| - | Drive Capi... | drivecapit... |
| - | Octagon Ca... | octagoninv... |
| - | RA Capital... | racap.com |
| 02.11.2022 | Xontogeny | xontogeny.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 12.09.2022 | Series C | $90M | - |
| 29.04.2021 | Series B | $120M | - |
| 21.07.2020 | Series A | $40M | - |
Mentions in press and media 14
| Date | Title | Description |
| 07.01.2026 | Ascidian Therapeutics and Forge Biologics Announce Manufacturing Partnership to Advance RNA Editing Therapy for Stargardt Disease | Forge’s FUEL™ platform and cGMP manufacturing services support the production of AAV for Ascidian’s ACDN-01, the most advanced genetic therapy targeting the underlying cause of Stargardt disease Collaboration secures clinical supply needed ... |
| 17.11.2025 | Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards | Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-... |
| 17.12.2024 | Fueling the Future of Gene Therapies with Manufacturing Innovation, Upcoming Webinar Hosted by Xtalks | www.forgebiologics.com In this free webinar, learn how adeno-associated virus (AAV) manufacturing innovations can accelerate program success. Attendees will gain insights into technical advancements in AAV platform manufacturing. The featur... |
| 13.11.2023 | These are the need-to-know biotech stories from this weekend | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Lots of news on the cardiovascular front this morning: We discuss Novo Nordisk’s plans in heart disease, and Verve’s... |
| 12.09.2022 | Forge Biologics Raises $90M in Series C Financing | Forge Biologics, a Columbus, OH-based provider of a gene therapy-focused contract development and manufacturing organization, raised $90M in Series C funding. The round. which brought total funding raised to date to $330m, was led by Drive ... |
| 12.09.2022 | Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms | • Total capital raised of $330 million since the Company’s launch in 2020 • Financing expands planned usage of Company’s 20 cGMP suites containing multiple 50L, 500L, 1,000L and 5000L bioreactors for research-to-commercial gene therapy man... |
| 10.01.2022 | Forge Biologics Closes $80 Million in Additional Financing to Accelerate Planned CDMO Expansion | Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today 2022 manufacturing expansion plans to meet the growing demand for gene therapy manufacturing. The expansion will coincide with an a... |
| 30.04.2021 | Forge Biologics picks up $120M for gene therapy development | Forge Biologics has raised a $120 million Series B led by RA Capital Management. Based in Columbus, Ohio, the company focuses on gene therapy contract development and manufacturing. Forge raised a $40 million round in July 2020. The startup... |
| 29.04.2021 | Forge Biologics Raises $120M in Series B Financing | Forge Biologics, a Columbus, Ohio-based gene therapy-focused contract development and manufacturing organization, closed a $120m Series B financing. The round was led by RA Capital Management with participation from Perceptive Advisors and ... |
| 29.04.2021 | Forge Biologics : Announces Closing of $120 Million Series B Financing | Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the closing of a $120 million Series B financing. The financing was led by RA Capital Management with participation from Perceptive... |
Show more